BE799728A - Procede pour la separation de steredoisomeres de certains steroides - Google Patents

Procede pour la separation de steredoisomeres de certains steroides

Info

Publication number
BE799728A
BE799728A BE131271A BE131271A BE799728A BE 799728 A BE799728 A BE 799728A BE 131271 A BE131271 A BE 131271A BE 131271 A BE131271 A BE 131271A BE 799728 A BE799728 A BE 799728A
Authority
BE
Belgium
Prior art keywords
steredoisomers
separation
certain steroids
steroids
certain
Prior art date
Application number
BE131271A
Other languages
English (en)
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Publication of BE799728A publication Critical patent/BE799728A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BE131271A 1972-05-19 1973-05-18 Procede pour la separation de steredoisomeres de certains steroides BE799728A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (fr) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
BE799728A true BE799728A (fr) 1973-09-17

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
BE131271A BE799728A (fr) 1972-05-19 1973-05-18 Procede pour la separation de steredoisomeres de certains steroides

Country Status (17)

Country Link
US (1) US3928326A (fr)
JP (1) JPS547794B2 (fr)
BE (1) BE799728A (fr)
CA (1) CA1003402A (fr)
CY (1) CY1012A (fr)
DE (1) DE2323216C3 (fr)
DK (1) DK133249C (fr)
FI (1) FI50711C (fr)
FR (1) FR2185406B1 (fr)
GB (1) GB1428416A (fr)
HK (1) HK49079A (fr)
IL (1) IL42154A (fr)
KE (1) KE2969A (fr)
NL (1) NL175917C (fr)
SE (1) SE378110B (fr)
SU (1) SU468408A3 (fr)
ZA (1) ZA732956B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
WO1994015947A1 (fr) * 1993-01-08 1994-07-21 Astra Aktiebolag Nouveaux derives steroidiens specifiques du colon ou de l'ileon
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
WO2005021515A2 (fr) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase de type iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US7750151B2 (en) 2004-04-09 2010-07-06 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1888050B1 (fr) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
WO2007045979A1 (fr) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
CA2664247A1 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase type iv
WO2008035316A2 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiestérase
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
KR101591656B1 (ko) 2007-01-10 2016-02-19 엠에스디 이탈리아 에스.알.엘. 폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
WO2008111009A1 (fr) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
EP2124944B1 (fr) * 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérase
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CN105175479B (zh) * 2009-09-11 2017-06-09 奇斯药制品公司 异噁唑烷衍生物
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
WO2011097594A2 (fr) 2010-02-08 2011-08-11 Kinagen, Inc. Methodes therapeutiques et compositions impliquant l'inhibition de la kinase allosterique
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (fr) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
HUE040025T2 (hu) 2012-08-24 2019-02-28 Univ Texas A HIF aktivitás heterociklusos modulátorai betegség kezelésére
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
CA2892361A1 (fr) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Utilisation d'un inhibiteur wee1 pour traiter un cancer caracterise par de faibles niveaux d'expression de proteines tyrosine et threonine kinases 1 (pkmyt1) associee a la membrane
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
EP3475275B1 (fr) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 5-trifluorométhyl-oxadiazoles substitués en 3-aryle et hétéroaryle en tant qu'inhibiteurs de l'histone désacétylase 6 (hdac6)
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
SG11202010909RA (en) 2018-05-09 2020-12-30 Regeneron Pharma Anti-msr1 antibodies and methods of use thereof
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
MX2022007535A (es) 2019-12-17 2022-09-23 Merck Sharp & Dohme Llc Inhibidores de prmt5.
WO2024049931A1 (fr) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Compositions pharmaceutiques à base d'inhibiteurs de la topoisomérase-1 dérivés de l'exatécan, et leurs utilisations
WO2024091437A1 (fr) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Charges utiles de lieur adc dérivées d'exatécan, compositions pharmaceutiques et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Also Published As

Publication number Publication date
DE2323216C3 (de) 1978-06-22
DE2323216A1 (de) 1973-11-29
HK49079A (en) 1979-07-27
ZA732956B (en) 1974-04-24
CA1003402A (en) 1977-01-11
FR2185406A1 (fr) 1974-01-04
IL42154A (en) 1976-12-31
FI50711B (fr) 1976-03-01
NL7306979A (fr) 1973-11-21
DK133249B (da) 1976-04-12
NL175917C (nl) 1985-01-16
CY1012A (en) 1979-11-23
NL175917B (nl) 1984-08-16
JPS547794B2 (fr) 1979-04-10
DK133249C (da) 1976-09-13
US3928326A (en) 1975-12-23
IL42154A0 (en) 1973-07-30
SE378110B (fr) 1975-08-18
GB1428416A (en) 1976-03-17
AU5525273A (en) 1974-11-07
KE2969A (en) 1979-07-20
SU468408A3 (ru) 1975-04-25
DE2323216B2 (de) 1977-11-03
JPS4941379A (fr) 1974-04-18
FI50711C (fi) 1976-06-10
FR2185406B1 (fr) 1976-12-31

Similar Documents

Publication Publication Date Title
BE799728A (fr) Procede pour la separation de steredoisomeres de certains steroides
RO63451A (fr) Procede pour la preparation du tri-p-toluensulfomate du s-adenosyle-1-methionine
FR2311576A1 (fr) Procede pour la separation des isotopes
BE768539A (fr) Procede de separation
RO64406A (fr) Procede pour la separation d'isoprene des melanges
BE744641A (fr) Procede pour la preparation de 2-mercapto-benzthiazol
BE776530A (fr) Procede pour la preparation de 5-vinylnorbornene-2
BE803171R (fr) Procede pour la separation de lactames
BE773013A (fr) Procede pour la preparation de peptides
BE768540A (fr) Procede de separation
BE806085A (fr) Procede pour la separation de neptunium de thorium
BE808316A (fr) Procede pour la preparation de beta-alcoxy-omega-lactames
BE772049A (fr) Procede pour la preparation de 4-oxocapronitrile
BE804574A (fr) Procede de separation des elements actinides
RO64631A (fr) Procede pour la separation du cobalt
BE803434A (fr) Procede de separation
BE754559A (fr) Procede pour la preparation de trimethylhydroquinone
BE787343A (fr) Procede pour la preparation de 17-(2-halogenoethylidene)- steroides
BE766238A (fr) Procede pour la preparation de piperidyl-steroides
BE792559A (fr) Procede pour la separation de lactames
RO63904A (fr) Procede pour la preparation du 1-nitro-anthraquinone
BE748143A (fr) Procede pour la preparation de piperidine
BE766147A (fr) Procede pour la preparation de steroides
BE807113A (fr) Procede pour la preparation de delta-cetoesters
BE783293A (fr) Procede de separation de nitrilotriacetates alcalins

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: DRACO A.B.

Effective date: 19930518